[A multicenter prospective randomized open comparative study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China].

To compare the efficacy and safety of tranexamic acid (TA) and norethisterone (NET) for the treatment of patients with ovulatory menorrhagia in China.
One hundred and thirty one patients with proven ovulatory menorrhagia from gynecologic clinics of 5 teaching hospitals located in 4 different cities in China were enrolled during Jul 2004 to Dec 2006. Among them 128 completed the study. Patients were randomly divided into two therapeutic regimen groups: TA 1 g thrice daily during menstrual cycle days (D) 1-5, 69 cases; or NET 5 mg twice daily on D19-26, 59 cases. The drugs were administered for 2 consecutive cycles, then withdrawn and patients were followed-up for 1 more cycle. Data on menstrual blood loss [estimated by pictorial blood assessment chart (PBAC)], length of menstrual periods, quality of life (QOL) evaluated by a 6 item health-related questionnaire were collected before, during each cycle and were compared.
Both treatments led to significant decreases of mean PBAC scores and shorter duration of menstrual periods, and improved the QOL ranking during the two treatment cycles. The mean percentages of PBAC decrements in the TA first and second cycles were significantly greater than those in the NET corresponding cycles(35% vs 17% , P = 0.004; 44% vs 34%, P = 0.04 respectively). The success rate of TA second cycle was higher than that of the NET second cycle (41% vs 24%, P = 0.04). Improvement of QOL ranking in the TA first cycle was also significantly better than those in the NET first cycle (P = 0.03). The percentage of patients with at least 1 adverse event in TA group (19%) was significantly lower than that in NET group (35%, P = 0.04). Patients' willingness to continue the treatment in the TA second and follow-up cycles (94%, 79% respectively) were significantly higher than those in the corresponding cycles of NET groups (79%, 59% respectively; P = 0.01, P = 0.02).
The regimen of TA 3 g daily during menstrual days 1-5 is a more effective and tolerable treatment than luteal phase norethisterone for patients with ovulatory menorrhagia.
AuthorsYi-Wen Zhang, Fang-Fang He, Zheng-Yi Sun, Shang-Wei Li, Shi-Liang Bi, Xiu-Ling Huang, Zan-Sun Cao, Shu-Lan Lü, Jun-Li Lu, Zhen-Yu Zhang, Yi-Min Zhu, He-Feng Huang, Mao-Hua Miao
JournalZhonghua fu chan ke za zhi (Zhonghua Fu Chan Ke Za Zhi) Vol. 43 Issue 4 Pg. 247-50 (Apr 2008) ISSN: 0529-567X [Print] China
PMID18843961 (Publication Type: Comparative Study, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Antifibrinolytic Agents
  • Tranexamic Acid
  • Norethindrone
  • Administration, Oral
  • Adult
  • Antifibrinolytic Agents (pharmacology, therapeutic use)
  • Female
  • Humans
  • Menorrhagia (drug therapy)
  • Menstruation (drug effects)
  • Middle Aged
  • Norethindrone (adverse effects, pharmacology, therapeutic use)
  • Prospective Studies
  • Quality of Life
  • Tranexamic Acid (adverse effects, pharmacology, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: